{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:06:51Z","timestamp":1764022011524,"version":"3.45.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10147-025-02901-3","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T04:59:07Z","timestamp":1761368347000},"page":"2387-2388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; durvalumab, cemiplimab, zongertinib, and taletrectinib for lung cancer, pirtobrutinib and atezolizumab for lymphoma, durvalumab for bladder cancer, panitumumab plus sotorasib for colorectal cancer, and vorasidenib for glioma"],"prefix":"10.1007","volume":"30","author":[{"given":"Noriomi","family":"Matsumura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Mandai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"2901_CR1","unstructured":"Pharmaceuticals and Medical Devices Agency (2025) List of approved drugs (in Japanese). https:\/\/www.pmda.go.jp\/review-services\/drug-reviews\/review-information\/p-drugs\/0010.html Accessed on 30 Sep 2025"},{"key":"2901_CR2","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach JV, Harpole D, Mitsudomi T et al (2023) Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med 389:1672\u20131684. https:\/\/doi.org\/10.1056\/NEJMoa2304875","journal-title":"N Engl J Med"},{"key":"2901_CR3","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","volume":"397","author":"A Sezer","year":"2021","unstructured":"Sezer A, Kilickap S, G\u00fcm\u00fc\u015f M et al (2021) Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet 397:592\u2013604. https:\/\/doi.org\/10.1016\/S0140-6736(21)00228-2","journal-title":"Lancet"},{"key":"2901_CR4","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","volume":"28","author":"M Gogishvili","year":"2022","unstructured":"Gogishvili M, Melkadze T, Makharadze T et al (2022) Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med 28:2374\u20132380. https:\/\/doi.org\/10.1038\/s41591-022-01977-y","journal-title":"Nat Med"},{"key":"2901_CR5","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1056\/NEJMoa2503704","volume":"392","author":"JV Heymach","year":"2025","unstructured":"Heymach JV, Ruiter G, Ahn MJ et al (2025) Zongertinib in previously treated HER2-mutant non-small-cell lung cancer. N Engl J Med 392:2321\u20132333. https:\/\/doi.org\/10.1056\/NEJMoa2503704","journal-title":"N Engl J Med"},{"key":"2901_CR6","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1200\/JCO-25-00275","volume":"43","author":"M P\u00e9rol","year":"2025","unstructured":"P\u00e9rol M, Li W, Pennell NA et al (2025) Taletrectinib in ROS1+ non-small cell lung cancer: TRUST. J Clin Oncol 43:1920\u20131929. https:\/\/doi.org\/10.1200\/JCO-25-00275","journal-title":"J Clin Oncol"},{"key":"2901_CR7","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1200\/JCO-25-00166","volume":"43","author":"JP Sharman","year":"2025","unstructured":"Sharman JP, Munir T, Grosicki S et al (2025) Phase III trial of pirtobrutinib versus idelalisib\/rituximab or bendamustine\/rituximab in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia\/small lymphocytic lymphoma (BRUIN CLL-321). J Clin Oncol 43:2538\u20132549. https:\/\/doi.org\/10.1200\/JCO-25-00166","journal-title":"J Clin Oncol"},{"key":"2901_CR8","unstructured":"Makita S, Koya J, Suzuki Y, et al (2024) Phase 2 study of anti-PD-L1 antibody atezolizumab in patients with relapsed\/refractory extranodal natural killer\/T-cell lymphoma: NCCH1903\/ATTACK study. European Hematology Association Library. 419257; P1170. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/419257\/shinichi.makita.phase.2.study.of.anti-pd-l1.antibody.atezolizumab.in.patients.html Accessed on 30 Sep 2025"},{"key":"2901_CR9","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles T, Catto JWF, Galsky MD et al (2024) Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med 391:1773\u20131786. https:\/\/doi.org\/10.1056\/NEJMoa2408154","journal-title":"N Engl J Med"},{"key":"2901_CR10","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih MG, Salvatore L, Esaki T et al (2023) Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N Engl J Med 389:2125\u20132139. https:\/\/doi.org\/10.1056\/NEJMoa2308795","journal-title":"N Engl J Med"},{"key":"2901_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, van den Bent MJ, Blumenthal DT et al (2023) Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med 389:589\u2013601. https:\/\/doi.org\/10.1056\/NEJMoa2304194","journal-title":"N Engl J Med"},{"key":"2901_CR12","unstructured":"Pharmaceuticals and Medical Devices Agency (2025) Revisions of PRECAUTIONS (FY2025). https:\/\/www.pmda.go.jp\/english\/safety\/info-services\/drugs\/revision-of-precautions\/0013.html Accessed on 30 Sep 2025"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02901-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02901-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02901-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:02:21Z","timestamp":1764021741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02901-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2901"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02901-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"assertion":[{"value":"25 October 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No author has any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}